AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.
Shruti GuptaSteven G CocaLili ChanMichal L MelamedSamantha K BrennerSalim Salim HayekAnne SutherlandSonika PuriAnand SrivastavaAmanda Leonberg-YooAlexandre M ShehataJennifer E FlytheArash RashidiEdward J SchenckNitender GoyalS Susan HedayatiRajany DyAnip BansalAmbarish AthavaleH Bryant NguyenAnitha VijayanDavid M CharytanCarl E SchulzeMin J JooAllon N FriedmanJingjing ZhangMarie Anne SosaEric JuddJuan Carlos Q VelezMary MallappallilRoberta E RedfernAmar D BansalJavier A NeyraKathleen D LiuAmanda D RenaghanMarta ChristovMiklos Z MolnarShreyak SharmaOmer KamalJeffery Owusu BoatengSamuel A P ShortAndrew J AdmonMeghan E SiseWei WangChirag R ParikhDavid E Leafnull nullPublished in: Journal of the American Society of Nephrology : JASN (2020)
AKI-RRT is common among critically ill patients with COVID-19 and is associated with a hospital mortality rate of >60%. Among those who survive to discharge, one in three still depends on RRT at discharge, and one in six remains RRT dependent 60 days after ICU admission.